GLP-1 S (Semaglutide)

Description

GLP-1 S (Semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is a modified analogue of the naturally occurring GLP-1 hormone, designed to have an extended half-life for once-weekly research protocols. Each Guardian Labs vial contains [Xmg] of lyophilized powder.

What is GLP-1 S (Semaglutide)?

Semaglutide acts by binding to and activating the GLP-1 receptor, a target found in pancreatic beta cells and specific regions of the brain.

• Mechanism: It mimics the action of endogenous GLP-1, promoting insulin secretion in a glucose-dependent manner and suppressing glucagon secretion.

• Gastric Emptying: Research indicates that GLP-1 agonists significantly delay gastric emptying, which modulates nutrient absorption rates.

Research Applications

GLP-1 S is the subject of extensive global research regarding metabolic syndrome and obesity.

1. Weight Management: Studies in animal and human models have consistently demonstrated that Semaglutide reduces energy intake by increasing satiety signals in the hypothalamus.

2. Glycemic Control: It is widely researched for its ability to lower HbA1c levels by improving insulin sensitivity and beta-cell function.

3. Cardiovascular Health: Ongoing research investigates its potential cardioprotective effects, including the reduction of major adverse cardiovascular events (MACE).

   ---

Published Research & Clinical Data

At Guardian Labs, we prioritize data-driven research. Below are the landmark trials regarding Semaglutide.

• Study 1: The STEP Trials (Weight Management)

  • Title: Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

  • Summary: The defining NEJM study showing that weekly Semaglutide administration resulted in a mean weight reduction of 14.9% compared to 2.4% in the placebo group.

  • Read the full study on NEJM

• Study 2: The SUSTAIN Trials (Glycemic Control)

  • Title: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)

  • Summary: This trial confirmed that Semaglutide significantly reduced the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in high-risk subjects.

  • Read the full study on NEJM

    ---

Storage and Handling

• Format: Sterile Lyophilized Powder.

• Storage: Store at -20°C (Freezer).

• Reconstitution: Reconstitute with bacteriostatic water. Avoid vigorous shaking.

Why Choose Guardian Labs?

Our GLP-1 S is subjected to rigorous HPLC analysis to ensure >99% purity. We provide the stability and consistency required for precise laboratory research. For bulk research inquiries, please Contact Us.

For Research Use Only: This product (GLP-1 S Semaglutide) is intended strictly for laboratory and research purposes. It is not intended for human consumption, injection, or use as a drug, food, or cosmetic.

Handling and Usage:

• This product should only be handled by qualified professionals or researchers.
• The material is supplied in a lyophilized (freeze-dried) state and requires reconstitution with bacteriostatic water or a sterile solvent.
• By purchasing this product, the buyer acknowledges that they understand the potential hazards associated with the handling of research chemicals.

Legal Compliance: Guardian Labs does not endorse the use of this product for performance enhancement or medical treatment. All buyers must be at least 18 years of age.